Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative FOLFOX versus postoperative risk-adapted chemotherapy for locally advanced rectal cancer with low local failure risk
2024-518077-34-00Phase 3Authorised
- Sponsor
- Heidelberg University
- Start
- Sep 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, capecitabine, fluorouracil and folinic acid in rectal adenocarcinoma (2 arms), sponsored by Heidelberg University. Primary endpoint: Disease-free survival. Planned start Sep 2020; status: authorised.
02
Drugs
oxaliplatincapecitabinefluorouracilfolinic acid
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2024-518077-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518077-34-00.